Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

39.71 +0.62 (+1.59%)
Streaming Delayed Price Updated: 10:18 AM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
How Risky Is Royalty Pharma’s Dividend? ↗
Royalty Pharma just announced a 5% dividend increase, its fourth raise in a row. It has boosted the dividend every year since it began paying one in 2020. The new $0.21 per share quarterly dividend... 
Via Talk Markets
News headline image
Top Stocks That Just Increased Their Dividends ↗
There are several reasons why investors tend to favor stocks that have had a dividend increase. 
Via Talk Markets
News headline image
NASDAQ:RPRX appears to be flying under the radar despite its strong fundamentals. ↗
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
NASDAQ:RPRX is an undervalued gem with solid fundamentals. ↗
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued. 
Via Chartmill
News headline image
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
NASDAQ:RPRX: good value for what you're paying. ↗
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued. 
Via Chartmill
News headline image
Royalty Pharma's Earnings Outlook ↗
 
Via Benzinga
News headline image
$10M Bet On GameStop? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Earnings Outlook For Royalty Pharma ↗
 
Via Benzinga
News headline image
Why PTC Therapeutics Soared 15% Higher Today ↗
The company scored a $1 billion upfront payment for expanding a commercial partnership. 
Via The Motley Fool
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
News headline image
Preview: Royalty Pharma's Earnings ↗
 
Via Benzinga
Ominous Death Cross Forms On Royalty Pharma's Chart ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
News headline image
2 Dividend Stocks Wall Street Thinks Can Rise by 50% ↗
These stocks could give investors the best of both worlds: dividend income and the potential to earn a great profit. 
Via The Motley Fool
News headline image
$122M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed mixed on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 32 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 64 companies achieved new lows for the year. 
Via Benzinga
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 129 stocks made new 52-week lows. 
Via Benzinga
News headline image
$12.5M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday, 79 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Insiders Selling TransMedics Group And 2 Other Stocks ↗
The Nasdaq 100 closed higher by around 0.7% on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023 ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
News headline image
Five Best And Worst Performing Healthcare Stocks In December 2022 ↗
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
News headline image
6 Stocks Warren Buffett Completely Exited in 2022 ↗
Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.